Accordingly, we examined the activation state of RhoA and its downstream actions in the PBMCs of lupus patients, and assessed the consequences of RhoA pathway inhibition on selected type I IFN-induced genes relevant to immune dysregulation. The gene discussed is RHOA; the disease is systemic lupus erythematosus.